<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35201675</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2162-3279</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Brain and behavior</Title><ISOAbbreviation>Brain Behav</ISOAbbreviation></Journal><ArticleTitle>C-reactive protein levels in patients with amyotrophic lateral sclerosis: A systematic review.</ArticleTitle><Pagination><StartPage>e2532</StartPage><MedlinePgn>e2532</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2532</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/brb3.2532</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting cortical and spinal motor neurons. There is a lack of optimal biomarkers to diagnose and prognosticate the ALS patients. C-reactive protein (CRP), an inflammatory marker, has shown promising results in ALS patients.</AbstractText><AbstractText Label="MATERIALS AND METHODS">PubMed, Embase, and Google Scholar databases were searched from 2000 to June 1, 2021 for suitable studies showing the relationship between CRP and ALS. The concentration of CRP levels was assessed between ALS patients and controls. Further, end outcomes like ALS functional rating scale (ALSFRS-R), survival status, and mortality risks were assessed in relation to CRP levels.</AbstractText><AbstractText Label="RESULTS">Eleven studies including five case-control, five cohorts, and one randomized control study were assessed. There were 2785 ALS patients and 3446 healthy controls. A significant increment in CRP levels among ALS patients in comparison with healthy controls were seen in most of the studies. ALSFRS-R and disease progression were found to be significantly correlated with CRP levels. Overall accuracy of CRP in CSF was 62% described in a single study.</AbstractText><AbstractText Label="CONCLUSION">Although CRP has shown promise as a prognostic biomarker, extensive cohort studies are required to assess its prognostic value and accuracy in diagnosing ALS taking into account the confounding factors.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kharel</LastName><ForeName>Sanjeev</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9591-3168</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Maharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Maharajgunj, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ojha</LastName><ForeName>Rajeev</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7680-7036</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Tribhuvan University Institute of Medicine, Maharajgunj, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preethish-Kumar</LastName><ForeName>Veeramani</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neurofoundation hospitals, Salem, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhagat</LastName><ForeName>Riwaj</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University Medical Center, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brain Behav</MedlineTA><NlmUniqueID>101570837</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C-reactive protein</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35201675</ArticleId><ArticleId IdType="pmc">PMC8933772</ArticleId><ArticleId IdType="doi">10.1002/brb3.2532</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arthur, K. C. , Calvo, A. , Price, T. R. , Geiger, J. T. , Chi&#xf2;, A. , &amp; Traynor, B. J. (2016) Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nature Communication, 7, 12408. 10.1038/ncomms12408</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacci, E. D. , Staniewska, D. , Coyne, K. S. , Boyer, S. , White, L. A. , Zach, N. , &amp; Cedarbaum, J. M. (2015). Item response theory analysis of the amyotrophic lateral sclerosis functional rating scale&#x2010;revised in the pooled resource open&#x2010;access ALS clinical trials database. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17(3&#x2013;4), 157&#x2013;167. Available from: 10.3109/21678421.2015.1095930</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1095930</ArticleId><ArticleId IdType="pubmed">26473473</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers, D. R. , Zhao, W. , Neal, D. W. , Thonhoff, J. R. , Thome, A. D. , Faridar, A. , Wen, S. , Wang, J. , &amp; Appel, S. H. (2020). Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Scientific Reports, 10(1),. Available from: 10.1038/s41598-020-72247-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-72247-5</ArticleId><ArticleId IdType="pmc">PMC7499429</ArticleId><ArticleId IdType="pubmed">32943739</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks, B. R. , Miller, R. G. , Swash, M. , &amp; Munsat, T. L . (2000) El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 1(5), 293&#x2010;299. 10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, R. H. , &amp; Al&#x2010;Chalabi, A. (2017) Amyotrophic lateral sclerosis. New England Journal of Medicine, 377(2), 162&#x2010;172. 10.1056/NEJMra1603471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Che&#x142;stowska, B. , &amp; Ku&#x17a;ma&#x2010;Kozakiewicz, M. (2020) Biochemical parameters in determination of nutritional status in amyotrophic lateral sclerosis. Neurology Science, 41(5), 1115&#x2010;1124. 10.1007/s10072-019-04201-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04201-x</ArticleId><ArticleId IdType="pubmed">31897946</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2;, A. , Logroscino, G. , Traynor, B. J. , Collins, J. , Simeone, J. C. , Goldstein, L. A. , &amp; White, L. A. (2013). Global epidemiology of amyotrophic lateral sclerosis: A systematic review of the published literature. Neuroepidemiology, 41(2), 118&#x2013;130. 10.1159/000351153</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Closhen, D. , Bender, B. , Luhmann, H. J. , &amp; Kuhlmann, C. R. W. (2010). CRP&#x2010;induced levels of oxidative stress are higher in brain than aortic endothelial cells [Internet]., 50, Cytokine, 117&#x2013;20. Available from: 10.1016/j.cyto.2010.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2010.02.011</ArticleId><ArticleId IdType="pubmed">20207160</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa, J. , &amp; de Carvalho, M. (2016) Emerging molecular biomarker targets for amyotrophic lateral sclerosis. Clinica Chimica Acta, 455, 7&#x2013;14. 10.1016/j.cca.2016.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2016.01.011</ArticleId><ArticleId IdType="pubmed">26774696</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui, C. , Sun, J. , Pawitan, Y. , Piehl, F. , Chen, H. , Ingre, C. , Wirdefeldt, K. , Evans, M. , Andersson, J. , Carrero, J.&#x2010;J. , &amp; Fang, F. (2020). Creatinine and C&#x2010;reactive protein in amyotrophic lateral sclerosis, multiple sclerosis and Parkinson's disease. Brain Communications, 2(2), fcaa152. 10.1093/braincomms/fcaa152</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa152</ArticleId><ArticleId IdType="pmc">PMC7850290</ArticleId><ArticleId IdType="pubmed">33543134</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver, M. , Lunetta, C. , Tarlarini, C. , Mosca, L. , Chio, A. , Van Damme, P. , &amp; Poesen, K. (2020). Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery &amp; Psychiatry, 91(4), 436&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">32029541</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon, P. H. (2013) Amyotrophic lateral sclerosis: An update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis, 04(5), 295&#x2013;310. 10.14336/AD.2013.0400295</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2013.0400295</ArticleId><ArticleId IdType="pmc">PMC3794725</ArticleId><ArticleId IdType="pubmed">24124634</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsuchou, H. , Kastin, A. J. , Mishra, P. K. , &amp; Pan, W. (2012) C&#x2010;reactive protein increases BBB permeability: Implications for obesity and neuroinflammation. Cellular Physiology and Biochemistry, 30(5), 1109&#x2010;1119. 10.1159/000343302</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000343302</ArticleId><ArticleId IdType="pmc">PMC4099000</ArticleId><ArticleId IdType="pubmed">23018453</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, F. , Zhu, Y. , Hsiao&#x2010;Nakamoto, J. , Tang, X. , Dugas, J. C. , Moscovitch&#x2010;Lopatin, M. , Glass, J. D. , Brown, R. H. , Ladha, S. S. , Lacomis, D. , Harris, J. M. , Scearce&#x2010;Levie, K. , Ho, C. , Bowser, R. , &amp; Berry, J. D. (2020). Longitudinal biomarkers in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 7(7), 1103&#x2013;1116. 10.1002/acn3.51078</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51078</ArticleId><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizman, D. , Rogowski, O. , Berliner, S. , Ish&#x2010;Shalom, M. , Maimon, N. , Nefussy, B. , Artamonov, I. , &amp; Drory, V. E. (2009). Low&#x2010;grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 119(6), 383&#x2013;389. 10.1111/j.1600-0404.2008.01112.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2008.01112.x</ArticleId><ArticleId IdType="pubmed">18976328</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby, P. , Ridker, P. M. , &amp; Hansson, G. K. (2009). Inflammation in atherosclerosis. Journal of the American College of Cardiology, 54(23), 2129&#x2013;2138. 10.1016/j.jacc.2009.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2009.09.009</ArticleId><ArticleId IdType="pmc">PMC2834169</ArticleId><ArticleId IdType="pubmed">19942084</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati, A. , Altman, D. G. , Tetzlaff, J. , Mulrow, C. , G&#xf8;tzsche, P. C. , Ioannidis, J. P. A. , Clarke, M. , Devereaux, P. J. , Kleijnen, J. , &amp; Moher, D. (2009) The PRISMA statement for reporting systematic reviews and meta&#x2010;analyses of studies that evaluate health care interventions: Explanation and elaboration. Journal of Clinical Epidemiology, 62, e1&#x2013;34. Available from: 10.1016/j.jclinepi.2009.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2009.06.006</ArticleId><ArticleId IdType="pubmed">19631507</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta, C. , Lizio, A. , Maestri, E. , Sansone, V. A. , Mora, G. , Miller, R. G. , Appel, S. H. , &amp; Chi&#xf2;, A. (2017). Serum C&#x2010;reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurology, 74(6), 660&#x2013;7. 10.1001/jamaneurol.2016.6179</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6179</ArticleId><ArticleId IdType="pmc">PMC5822215</ArticleId><ArticleId IdType="pubmed">28384752</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoud, F. A. , &amp; Rivera, N. I. (2002) The role of C&#x2010;reactive protein as a prognostic indicator in advanced cancer. Current Oncology Reports, 4(3), 250&#x2010;255. 10.1007/s11912-002-0023-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11912-002-0023-1</ArticleId><ArticleId IdType="pubmed">11937016</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley, M. E. , &amp; Baloh, R. H. (2019) Inflammation in ALS/FTD pathogenesis. Acta Neuropathologica, 137(5), 715&#x2010;730. 10.1007/s00401-018-1933-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1933-9</ArticleId><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, R. G. , Block, G. , Katz, J. S. , Barohn, R. J. , Gopalakrishnan, V. , Cudkowicz, M. , Zhang, J. R. , McGrath, M. S. , Ludington, E. , Appel, S. H. , &amp; Azhir, A. (2015). Randomized phase 2 trial of NP001, a novel immune regulator. Neurology &#x2010; Neuroimmunology Neuroinflammation, 2(3), e100. 10.1212/NXI.0000000000000100</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000100</ArticleId><ArticleId IdType="pmc">PMC4396529</ArticleId><ArticleId IdType="pubmed">25884010</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel, G. , Peter, R. S. , Rosenbohm, A. , Koenig, W. , Dupuis, L. , Rothenbacher, D. , &amp; Ludolph, A. C. (2017). Adipokines, C&#x2010;reactive protein and amyotrophic lateral sclerosis &#x2013; results from a population&#x2010;based ALS registry in Germany. Scientific Reports, 7(1), 4374. 10.1038/s41598-017-04706-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04706-5</ArticleId><ArticleId IdType="pmc">PMC5491500</ArticleId><ArticleId IdType="pubmed">28663573</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson, T. A. , Mensah, G. A. , Alexander, R. W. , Anderson, J. L. , Cannon, R. O. , Criqui, M. , Fadl, Y. Y. , Fortmann, S. P. , Hong, Y. , Myers, G. L. , Rifai, N. , Smith, S. C. , Taubert, K. , Tracy, R. P. , &amp; Vinicor, F. (2003). Markers of inflammation and cardiovascular disease. Circulation, 107(3), 499&#x2013;511. 10.1161/01.CIR.0000052939.59093.45</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000052939.59093.45</ArticleId><ArticleId IdType="pubmed">12551878</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips, T. , &amp; Robberecht, W. (2011) Neuroinflammation in amyotrophic lateral sclerosis: Role of glial activation in motor neuron disease. Lancet Neurology, 10(3), 253&#x2010;263. 10.1016/S1474-4422(11)70015-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70015-1</ArticleId><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryberg, H. , An, J. , Darko, S. , Lustgarten, J. L. , Jaffa, M. , Gopalakrishnan, V. , Lacomis, D. , Cudkowicz, M. , &amp; Bowser, R. (2010). Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle &amp; Nerve, 42(1), 104&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2975276</ArticleId><ArticleId IdType="pubmed">20583124</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjak, M. et&#xa0;al(2018) C&#x2010;reactive protein (CRP) is significantly higher in amyotrophic lateral sclerosis (ALS) patients on non&#x2010;invasive ventilation (NIV) and tracheostomy&#x2010;invasive ventilation (TIV) compared with ALS patients at intake clinic evaluation and decreases following riluzole administration &#x2013; Is CRP potentially a biomarker for treatment responsiveness? (P4.447). Neurology, 90.15 Supplement, P4.447. Web. 18 June. 2021.</Citation></Reference><Reference><Citation>Sun, J. , Carrero, J. J. , Zagai, U. , Evans, M. , Ingre, C. , Pawitan, Y. , &amp; Fang, F. (2020). Blood biomarkers and prognosis of amyotrophic lateral sclerosis. European Journal of Neurology, 27(11), 2125&#x2013;2133. 10.1111/ene.14409</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14409</ArticleId><ArticleId IdType="pubmed">32557963</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner, M. R. , Kiernan, M. C. , Leigh, P. N. , &amp; Talbot, K. (2009) Biomarkers in amyotrophic lateral sclerosis. Lancet Neurology, 8(1), 94&#x2013;109. 10.1016/S1474-4422(08)70293-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70293-X</ArticleId><ArticleId IdType="pubmed">19081518</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng, H.&#x2010;J. , Debray, T. P. A. , Visser, A. E. , van Eijk, R. P. A. , Rooney, J. P. K. , Calvo, A. , Martin, S. , McDermott, C. J. , Thompson, A. G. , Pinto, S. , Kobeleva, X. , Rosenbohm, A. , Stubendorff, B. , Sommer, H. , Middelkoop, B. M. , Dekker, A. M. , van Vugt, J. J. F. A. , van Rheenen, W. , Vajda, A. , &#x2026;, van den Berg, L. H. (2018). Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model. The Lancet Neurology, 17(5), 423&#x2013;433. 10.1016/S1474-4422(18)30089-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, W. , Beers, D. R. , &amp; Appel, S. H. (2013) Immune&#x2010;mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J Neuroimmune Pharmacol, 8(4), 888&#x2010;899. 10.1007/s11481-013-9489-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>